Did the FDA Approve KPV? What the July 23–24, 2026 Advisory-Committee Vote Actually Did

No, the FDA did not approve KPV. On July 23, 2026 the FDA’s Pharmacy Compounding Advisory Committee — the outside panel that advises the agency, abbreviated PCAC — voted 8–6, with one abstention, to recommend that KPV be added to the 503A bulks list, which names the ingredients a state-licensed pharmacy may use when compounding for an individual patient.

The committee cannot change that list, FDA may disagree with it, and formal rulemaking has not run. KPV is an unapproved drug today. It is a tripeptide, described in the literature as a fragment related to alpha-MSH, and the research most often cited for it is a 2008 gastroenterology paper on intestinal inflammation in an experimental model — not a clinical trial in patients.

KPV is unusual among the seven in that comparatively few people encounter it on its own. It most often turns up as a component inside multi-peptide blends — KLOW, for instance, combines GHK-Cu, KPV, BPC-157 and TB-500 in a single preparation.

This matters more than it might seem after a favourable vote. A 503A bulks-list recommendation addresses one substance at a time. It says nothing about a four-peptide mixture, and there are no large human trials of the KLOW combination itself. The arithmetic also does not work in the blend’s favour: of those four components, injectable GHK-Cu is not among the substances recommended at all — its nomination was withdrawn in April 2026 and never reinstated.

So a marketing line that reads "FDA panel backs the ingredients in our blend" is wrong on two counts at once. Nothing was backed in the sense of approval, and not every ingredient was even in front of the committee.

KPV, BPC-157 and TB-500 each drew exactly 8 in favour and 6 against with a single abstention on July 23. MOTS-c, heard the same day, came in at 7–5 with two abstentions.

Three identical tallies across three chemically unrelated substances suggests the panel largely voted the day-one slate as a block rather than reaching sharply different judgments compound by compound. That is worth knowing in KPV’s case specifically, because it is by some distance the least-marketed and least-discussed of the three, yet it carries precisely the same number as the most heavily promoted peptide on the agenda. The tally reflects how a committee voted on a particular afternoon. It is not a measure of evidence, and it should not be read as one.

A substance gets nominated for the 503A bulks list. FDA reviews it and may put it in front of the advisory committee. The committee hears the evidence and votes a recommendation, which is where KPVis now — and that recommendation is non-binding. FDA then decides whether to act, and if it does, it must run formal rulemaking: a proposed rule, a public comment period, and a final rule. Only at the end of that does a substance actually appear on the list. Not one rung of that ladder is FDA approval.

A recommendation to add a substance to the 503A bulks list is a decision about pharmacy compounding eligibility. It is not FDA approval, which is a separate pathway in which a sponsor submits clinical evidence for a specific finished product.

It is also worth being precise about what this vote was not. These substances came off FDA’s 503A Category 2 list — the “significant safety risk” designation — back in April 2026, when their nominations were withdrawn, and that did not move them to Category 1. The July vote was a separate, later step: a recommendation to add them to a permission list. Coming off a restriction list in April and being recommended for a permission list in July are two different actions, months apart, and merging them into a single “ban lifted” story misstates both. The full sequence is on our FDA peptide compounding status page, and what has to happen next is laid out separately.

Nothing today. If a clinic or an online seller tells you the FDA just approved KPV, or that it is newly legal and you should act before the window closes, that is a sales pitch resting on a misreading of a procedural vote. The rules governing what a pharmacy may compound are the same this week as last week. You can check one piece of that yourself in about ten seconds: FDA’s own 503A category list still carries its May 14, 2026 update date, because these votes did not change it.

Anything sold to you in the meantime as “research use only” is not a prescription, is not dispensed by a licensed pharmacy, and carries no guarantee about what is actually in it. Given that FDA’s own chemists told the committee they could not always say what these compounds are, that is not an abstract concern. If you want the clinical picture for this substance rather than the regulatory one, see the KPV overview; for state law, see is peptide therapy legal in Nevada.